New medical imaging
equipment provides early detection of skin cancer
28 June 2004
Could You Have Skin Cancer? Do
you know if you have skin cancer or if you have skin lesions that could
develop into skin cancer? Early detection of these ticking time bombs
enhances survival.
A new and unrivalled medical system available now in Australia, and soon to
be available in the US, is delivering a new dimension in skin cancer
screening and proactive patient care.
MicroDERM medical imaging equipment and Expert System multi-application
software is capable of scanning, recording, comparing, and analysing skin
lesions to aid the clinical diagnosis of skin cancer. Used as part of an
on-going patient management system it can be used initially to detect skin
cancer and subsequently to monitor subtle adverse changes in skin lesions.
Thus, MicroDERM and Expert System deliver a complete point-of-care patient
management system for doctors and their patients, but this is just the tip
of this iceberg.
The Expert System software is based on the three-year Diagnostic and Neural
Analysis of Skin Cancer (DANAOS) study that was conducted collaboratively by
nine European countries between July 1997 and December 2000. The study
proved the Expert System achieved the same level of performance as was
achieved, on average, by specialist Dermatologists.
Results of the DANAOS study were published in the respected British Journal
of Dermatology (ref BJD 2003; 149: 801-809).
The clinical data collected during the DANAOS study forms the foundation of
the Expert System. Visiomed Group Ltd located in Perth, Western Australia
owns the exclusive worldwide rights to this data. This means Visiomed's
Expert System is unrivalled by any comparative system.
The Expert System applies the widely accepted ABCD rule when comparing skin
lesions against the database. This means the software applies the same
four-pronged analysis as would be applied by a specialist Dermatologist ,
but these parameters are further broken down into more than 40 variables
that are interrogated by the Expert System.
Remarkably, the Expert System is capable of achieving even better results as
it learns while it works. Over time the expanding database will lead to
increased levels of accuracy, after the results have been centrally updated
by Visiomed Group at its German research facilities.
Equal accessibility to quality healthcare is a concern for all governments.
In remote areas where specialists are few and far between, the system could
facilitate a first opinion to be confirmed/seconded via e-health links.
Patients have increasing expectations of their medical practitioners. The
Expert System facilitates proactive patient care via a patient management
system. Skin lesions (once on record within the patient management system)
can be monitored via periodic check-ups to detect adverse change. In this
way, the system acts as an early warning or delivers peace of mind to
patients.
Doctors may also achieve time-saving benefits by training clinic nurses to
operate the system under supervision.
Both microDERM and Expert System are TGA approved in Australia. The FDA
recently approved the microDERM equipment and patient management system,
opening the door to initial sales of MicroDERM in the US. Visiomed plans a
subsequent FDA application for the Expert System this year. Approval would
result in a 'world first'.
The owner of the MicroDERM Expert System equipment, patents, and
intellectual property, Visiomed, is presently seeking high profile partners
to assist with their 'world first' US roll-out of the MicroDERM Expert
System.
MicroDERM and Expert System are both platform technologies. In the future
microDERM equipment can be adapted for multiple applications, eg; changing
the light could enable scanning for eye disease, and a software upgrade
could aid diagnostics.
Expert System software is currently being developed for additional
applications.
Visiomed (www.visiomed.com.au) is a medical devices group with worldwide
rights in the medical field to intellectual property covering the use of
proprietary computer based expert systems for the imaging, diagnosis and
management of diseases and other conditions.
Visiomed holds an exclusive distributorship in Australia for Siemens Medical
Equipment.
The company also owns the worldwide rights to the Funhaler (www.funhaler.com),
a paediatric incentive spacer used to deliver aerosol-based asthma drugs.
The Funhaler is covered by issued and pending patents. The Funhaler is
expected to be launched into major international markets in the first half
of 2005.
For further information, please contact Visiomed's Dr Sassine on (08) 9321
2712 (international 618 9321 2712), or mobile 0412 533 966. Email:
[email protected]